Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poor prognosis. Large gains were made in the first decade of the new century when clinical ...

Brexucabtagene autoleucel approval marked a significant advancement in MCL treatment, achieving a 62% complete remission rate in resistant or relapsed patients. Prognostic tools like the Ki-67 index ...

Among the 68 evaluable patients, the overall response rate was 85.3%, with 67.6% of patients achieving complete response and 17.6% achieving partial response. The Food and Drug Administration (FDA) ...

Findings showed acalabrutinib with bendamustine and rituximab (BR) reduced the risk of disease progression or death by 27% compared with placebo plus BR. The Food and Drug Administration (FDA) has ...

Mantle cell lymphoma is the fourth subtype of non-Hodgkin lymphoma that can be treated with this CAR T-cell therapy. Bristol Myers Squibb today announced 1 that FDA has approved lisocabtagene ...

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...

People with mantle cell lymphoma (MCL) often need to try different treatments to control their cancer. MCL can be hard to treat because it is aggressive and usually not curable. Jaypirca offers a new ...

Please provide your email address to receive an email when new articles are posted on . Tandem-target CAR-T produced a response in all participants with relapsed or refractory mantle cell lymphoma in ...

In this video, Ann S. LaCasce, MD, MMSc, discusses highlights in mantle cell lymphoma presented at ASH Annual Meeting and Exposition.

Translocations are chromosomal “cut and paste” errors that drive many lymphomas, a type of blood cancer and the sixth most common form of cancer overall. This includes mantle cell lymphoma, a rare but ...